|
PRCC expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.45992115566196E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.05380198695593E-12 |
| Normal-vs-Stage2 |
1.15299999992047E-07 |
| Normal-vs-Stage3 |
2.69979594236247E-11 |
| Normal-vs-Stage4 |
3.52689999427724E-09 |
| Stage1-vs-Stage2 |
9.271800E-01 |
| Stage1-vs-Stage3 |
4.896200E-01 |
| Stage1-vs-Stage4 |
5.167400E-01 |
| Stage2-vs-Stage3 |
7.021000E-01 |
| Stage2-vs-Stage4 |
6.594600E-01 |
| Stage3-vs-Stage4 |
9.125200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.36188887628941E-13 |
| Normal-vs-AfricanAmerican |
3.429800E-02 |
| Normal-vs-Asian |
5.03809993723792E-10 |
| Caucasian-vs-AfricanAmerican |
8.521900E-03 |
| Caucasian-vs-Asian |
9.763800E-01 |
| AfricanAmerican-vs-Asian |
4.659600E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.64829999333472E-09 |
| Normal-vs-Female |
1.9693136010801E-12 |
| Male-vs-Female |
2.244000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.29950503083387E-11 |
| Normal-vs-Age(41-60Yrs) |
6.49591491708179E-12 |
| Normal-vs-Age(61-80Yrs) |
6.60479999581298E-08 |
| Normal-vs-Age(81-100Yrs) |
1.135540E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.276400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.353400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.821600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.946600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.258600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.665400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.220680E-04 |
| Classical-VS-Follicular |
3.363600E-01 |
| Classical-VS-Other |
4.962400E-01 |
| Classical-VS-Normal |
4.2773995456713E-10 |
| Tall-VS-Follicular |
9.018300E-03 |
| Tall-VS-Other |
4.711200E-01 |
| Tall-VS-Normal |
1.92523774700248E-12 |
| Follicular-VS-Other |
7.680200E-01 |
| Follicular-VS-Normal |
3.15310000331692E-09 |
| Other-VS-Normal |
1.183400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.90709670278011E-11 |
| Normal-vs-N1 |
6.25055562863963E-14 |
| N0-vs-N1 |
1.016420E-02 |
|
|
